Wall Street brokerages expect China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to post earnings per share (EPS) of $1.11 for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $0.95 in the same quarter last year, which indicates a positive year over year growth rate of 16.8%. The business is expected to report its next earnings results on Thursday, February 22nd.
According to Zacks, analysts expect that China Biologic Products will report full-year earnings of $5.22 per share for the current year, with EPS estimates ranging from $5.17 to $5.26. For the next financial year, analysts expect that the company will report earnings of $5.75 per share, with EPS estimates ranging from $5.49 to $6.00. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover China Biologic Products.
A number of analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Monday, January 29th. BidaskClub upgraded shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $137.50.
Shares of China Biologic Products (CBPO) opened at $80.85 on Monday. China Biologic Products has a 1 year low of $72.21 and a 1 year high of $120.46. The company has a market cap of $2,678.59, a PE ratio of 20.37, a P/E/G ratio of 1.02 and a beta of 1.67.
ILLEGAL ACTIVITY NOTICE: “China Biologic Products Holdings, Inc. (CBPO) Expected to Announce Earnings of $1.11 Per Share” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/02/19/china-biologic-products-holdings-inc-cbpo-expected-to-announce-earnings-of-1-11-per-share.html.
About China Biologic Products
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.